Detalles de la búsqueda
1.
Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
Pharm Biol
; 62(1): 33-41, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100532
2.
Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study.
Cancer Sci
; 114(6): 2552-2559, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36851884
3.
Notch signaling pathway: architecture, disease, and therapeutics.
Signal Transduct Target Ther
; 7(1): 95, 2022 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35332121
4.
The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.
Ann Palliat Med
; 10(6): 7088-7094, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33832284
5.
Coexisting of COX7A2L-ALK, LINC01210-ALK, ATP13A4-ALK and Acquired SLCO2A1-ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report.
Onco Targets Ther
; 13: 8313-8316, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32903930
6.
Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Ann Palliat Med
; 9(5): 3609-3613, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32648452
Resultados
1 -
6
de 6
1
Próxima >
>>